Endpoints News 生物医药· Kyle LaHucik·· 17 天前AI 评分33
达萨利亚药物sevasemten肌营养不良临床试验失败
Servier's $1.5B bet on Edgewise drug fails five months in
AI 导读
达萨利亚公司斥资15.5亿美元购入的肌营养不良药物sevasemten在关键试验中失败。该试验仅进行五个月即宣告失败。
正文
The muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial.
The drug, called sevasemten, failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news